A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis

NCT03443024 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

280

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

BIOLOGICAL: Lebrikizumab
DRUG: Placebo

Sponsor

Eli Lilly and Company

Collaborators

[object Object]